{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"1.7","value":"1.4"},{"groupId":"OG001","lowerLimit":"2.4","upperLimit":"3.0","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"378"}],"units":"Participants"}],"description":"Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the intention To Treat (ITT) population. The ITT population is composed of all randomized patients (i.e. patients assigned to a treatment group by the randomization, regardless of whether patients received any study drug or received a different study drug from which they were randomized).","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to 104 weeks (study cut-off)","title":"Time to Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}